CD8A and neoplasm: Very recently, the number and frequency of NeoAg-specific CD8+ T-cells were confirmed to be associated with the clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) by using an elegant approach [26].